Salient Private Client’s GSK GSK Stock Holding History

Salient Private Client’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,052	Closed	-$393K	–	124
2018 Q1	$393K	Buy	+8,052	New	+$375K	0.07%	117

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Salient Private Client's GSK Position: Q2 2018 in Review

Salient Private Client sold out of GSK (GSK) in Q2 2018, closing a stake of 8,052 shares — an estimated $393K sold.

Salient Private Client first reported a position in GSK in Q1 2018 and held it in 1 quarter. The position peaked at $393K in Q1 2018. 787 funds tracked by Wall St. Rank hold GSK as of Q2 2018.

Salient Private Client reported no remaining GSK position as of Q2 2018 after selling out during the quarter.
Salient Private Client sold 8,052 GSK shares in Q2 2018, an estimated $393K.
Salient Private Client first reported a position in GSK in Q1 2018 and held it in 1 quarter.
Salient Private Client's GSK position peaked at $393K in Q1 2018.
787 funds tracked by Wall St. Rank held GSK as of Q2 2018.

Based on Salient Private Client's 13F filing for Q2 2018, filed 1 Aug 2018.